Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1986 1
1987 2
1989 4
1990 1
1992 1
1993 2
1995 1
1999 1
2001 1
2003 1
2006 4
2007 1
2008 1
2009 2
2010 3
2011 1
2013 2
2014 5
2015 5
2017 1
2018 3
2019 5
2020 5
2021 4
2022 1
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for emilia blasted
Your search for Emilia Blåsten retrieved no results
Ivosidenib in acute myeloid leukemia.
Bruzzese A, Labanca C, Martino EA, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2093-2100. doi: 10.1080/14656566.2023.2272659. Epub 2024 Jan 5. Expert Opin Pharmacother. 2023. PMID: 37874005 Review.
AREAS COVERED: Ivosidenib, the first-in-class, selective, allosteric IDH1R132 inhibitor, showed the capability to induce in vitro differentiation of primary mIDH1 AML blasts. Clinical data highlighted its exceptional safety profile, as a standalone therapy and in combinati …
AREAS COVERED: Ivosidenib, the first-in-class, selective, allosteric IDH1R132 inhibitor, showed the capability to induce in vitro differenti …
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
Calabresi L, Carretta C, Romagnoli S, Rotunno G, Parenti S, Bertesi M, Bartalucci N, Rontauroli S, Chiereghin C, Castellano S, Gentili G, Maccari C, Vanderwert F, Mannelli F, Della Porta M, Manfredini R, Vannucchi AM, Guglielmelli P. Calabresi L, et al. Am J Hematol. 2023 Oct;98(10):1520-1531. doi: 10.1002/ajh.27013. Epub 2023 Jul 3. Am J Hematol. 2023. PMID: 37399248
Transformation from chronic (CP) to blast phase (BP) in myeloproliferative neoplasm (MPN) remains poorly characterized, and no specific mutation pattern has been highlighted. ...
Transformation from chronic (CP) to blast phase (BP) in myeloproliferative neoplasm (MPN) remains poorly characterized, and no specif …
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
Bruzzese A, Martino EA, Mendicino F, Lucia E, Olivito V, Capodanno I, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Eur J Haematol. 2024 Jun;112(6):860-869. doi: 10.1111/ejh.14181. Epub 2024 Jan 31. Eur J Haematol. 2024. PMID: 38294126 Review.
Presently, the World Health Organization (WHO) classification of myeloid neoplasms recognizes a specific subtype of MDS known as "myelodysplastic neoplasm with low blast and isolated del(5q)" identified by the sole presence of 5q deletion or in combination with one other a …
Presently, the World Health Organization (WHO) classification of myeloid neoplasms recognizes a specific subtype of MDS known as "myelodyspl …
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence.
Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S, Huang X. Darici S, et al. J Clin Med. 2020 Sep 11;9(9):2934. doi: 10.3390/jcm9092934. J Clin Med. 2020. PMID: 32932888 Free PMC article. Review.
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, …
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of …
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Palandri F, Palumbo GA, Bonifacio M, Elli EM, Tiribelli M, Auteri G, Trawinska MM, Polverelli N, Benevolo G, Tieghi A, Cavalca F, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Venturi M, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Branzanti F, Vianelli N, Cavo M, Heidel F, Iurlo A, Breccia M. Palandri F, et al. Cancers (Basel). 2023 Oct 17;15(20):5027. doi: 10.3390/cancers15205027. Cancers (Basel). 2023. PMID: 37894394 Free PMC article.
Overall, 172 patients were alive on ruxolitinib after 5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib after 5 yrs (short-term RUX, STR), and 123 patients died while on ruxolitinib after <5 yrs (early death on ruxolitinib, EDR). The cumulative …
Overall, 172 patients were alive on ruxolitinib after 5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib afte …
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Forghieri F, Nasillo V, Paolini A, Bettelli F, Pioli V, Giusti D, Gilioli A, Colasante C, Acquaviva G, Riva G, Barozzi P, Maffei R, Potenza L, Marasca R, Fozza C, Tagliafico E, Trenti T, Comoli P, Longo G, Luppi M. Forghieri F, et al. Int J Mol Sci. 2020 Nov 26;21(23):8975. doi: 10.3390/ijms21238975. Int J Mol Sci. 2020. PMID: 33255988 Free PMC article. Review.
Caution is also suggested in definitely diagnosing NPM1-mutated MNs with blast count <20%, since NPM1-mutated AML cases frequently present dysplastic features and multilineage bone marrow cells showing abnormal cytoplasmic NPM1 protein delocalization by immunohistochemi …
Caution is also suggested in definitely diagnosing NPM1-mutated MNs with blast count <20%, since NPM1-mutated AML cases frequently …
Inhibition of Ras-mediated signaling pathways in CML stem cells.
Bertacchini J, Ketabchi N, Mediani L, Capitani S, Marmiroli S, Saki N. Bertacchini J, et al. Cell Oncol (Dordr). 2015 Dec;38(6):407-18. doi: 10.1007/s13402-015-0248-2. Epub 2015 Oct 12. Cell Oncol (Dordr). 2015. PMID: 26458816 Review.
CONCLUSIONS: A closer investigation of the influence of Ras-mediated signaling pathways on CML progression to blast crisis is warranted to uncover new directions for targeted therapies, particularly in cases that are resistant to current tyrosine kinase inhibitors....
CONCLUSIONS: A closer investigation of the influence of Ras-mediated signaling pathways on CML progression to blast crisis is warrant …
Mechanisms in endocrinology: Genetics of FSH action: a 2014-and-beyond view.
Simoni M, Casarini L. Simoni M, et al. Eur J Endocrinol. 2014 Feb 4;170(3):R91-107. doi: 10.1530/EJE-13-0624. Print 2014 Mar. Eur J Endocrinol. 2014. PMID: 24288354 Free article. Review.
.-29G>A) in FSHR, and rs10835638 (c.-211G>T) in FSHB. Literature search via PubMed. Blast analysis of genomic information available in the NCBI nucleotide database. ...
.-29G>A) in FSHR, and rs10835638 (c.-211G>T) in FSHB. Literature search via PubMed. Blast analysis of genomic information avail …
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Zambrotta GPM, Nicolini FE, Assouline S, Busque L, Pungolino E, Abruzzese E, Miggiano MC, Elena C, Alvarez-Larran A, Triguero A, Iurlo A, Bucelli C, Cerrano M, Capodanno I, Lunghi F, le Coutre P, Galimberti S, Caocci G, Maffioli M, Stagno F, Saussele S, Piazza R, Druker BJ, Fava C, Guglielmana V, Colombo F, Antolini L, Gambacorti-Passerini C. Zambrotta GPM, et al. Am J Hematol. 2023 Nov;98(11):1762-1771. doi: 10.1002/ajh.27073. Epub 2023 Aug 30. Am J Hematol. 2023. PMID: 37647134
Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. ...
Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatme …
A literature review of the military uses of silver-nylon dressings with emphasis on wartime operations.
Barillo DJ, Pozza M, Margaret-Brandt M. Barillo DJ, et al. Burns. 2014 Dec;40 Suppl 1:S24-9. doi: 10.1016/j.burns.2014.09.017. Burns. 2014. PMID: 25418434 Review.
Medical support of military operations involves treatment of massive soft tissue wounds, thermal burns, open fractures, blast injuries and traumatic amputations under conditions that are often austere and far from supply lines. ...
Medical support of military operations involves treatment of massive soft tissue wounds, thermal burns, open fractures, blast injurie …
67 results